Nurix Therapeutics Inc

For the period ended Nov 30, 2024. Filed Jan 28, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Jan 28, 2025

NRIX$15.88-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

	Year Ended November 30,
	2024	2023	2022
Cash flows from operating activities
Net loss	$(193,569)	$(143,948)	$(180,360)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	9,318	7,533	5,349
Stock-based compensation	33,929	33,673	28,131
Net amortization (accretion) of premium (discount) on marketable securities	(11,288)	(5,421)	426
Loss on disposal of property and equipment	31	556	9
Amortization of operating lease right-of-use assets	7,110	6,121	5,459
Other	286	—	201
Changes in operating assets and liabilities:
Accounts receivable	—	—	6,000
Prepaid expenses and other assets	(459)	2,139	(1,094)
Accounts payable	5,209	1,614	85
Deferred revenue	(28,549)	19,513	(26,627)
Operating lease liabilities	(6,418)	(6,268)	(4,871)
Accrued expenses and other current liabilities	11,816	3,123	7,485
Net cash used in operating activities	(172,584)	(81,365)	(159,807)
Cash flows from investing activities
Purchases of marketable securities	(707,953)	(246,334)	(239,366)
Maturities of marketable securities	459,513	323,036	278,808
Purchases of property and equipment	(9,273)	(8,401)	(12,244)
Net cash (used in) provided by investing activities	(257,713)	68,301	27,198
Cash flows from financing activities
Proceeds from issuances of common stock and pre-funded warrants in equity financing, net of issuance costs	188,732	—	94,759
Proceeds from issuances of common stock in "at the market" financing, net of issuance costs	289,763	—	19,400
Proceeds from exercise of stock options and pre-funded warrants	5,055	988	1,078
Proceeds from issuance under employee stock purchase plan	2,132	2,229	1,955
Repurchase of unvested early exercised stock options	(15)	—	—
Net cash provided by financing activities	485,667	3,217	117,192
Net increase (decrease) in cash, cash equivalents and restricted cash	55,370	(9,847)	(15,417)
Cash, cash equivalents and restricted cash at beginning of period	55,528	65,375	80,792
Cash, cash equivalents and restricted cash at end of period	$110,898	$55,528	$65,375
Supplemental disclosures of non-cash investing and financing activities:
Additions to property and equipment included in accounts payable and accrued expenses and other current liabilities	$1,643	$632	$1,373
Right-of-use assets recognized in exchange for lease obligations	$4,107	$23,995	$5,068
Capitalized stock-based compensation related to internal-use software development	$14	$74	$69
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities	$117	$—	$—
Deferred issuance costs recognized related to the "at the market" financing	$394	$—	$72
Vesting of early exercised stock options	$33	$117	$145

	As of November 30,
	2024	2023	2022
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$109,997	$54,627	$64,474
Restricted cash	901	901	901
Total cash, cash equivalents and restricted cash	$110,898	$55,528	$65,375

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.